Apeiron Announces Start of a Phase I Trial with a Unique Cellular Anti Cancer Therapy Triggering Immunological Checkpoint Blockade

Apeiron’s project APN401, based on the collection, stimulation and subsequent re-administration of a patient’s immune cells, is being investigated in a clinical phase I trial performed at a renowned, academic medical center in the United States.

Press release